In several malignancies originating from non-gluconeogenic organs, such as glioblastoma, ovarian cancer, gastric cancer, and cervical carcinoma, elevated G6PC1 expression has been detected and is associated with enhanced tumor aggressiveness and metastatic potential (10, 57–59). This evidence concerns the gene G6PC1 and neoplasm.